Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone

Bertalan Németh, Anett Molnár, Ron Akehurst, Margit Horváth, Kristóf Kóczián, György Németh, Árpád Götze, Z. Vokó

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: Our study aimed at estimating differences in quality-adjusted life year (QAlY) gain for patients with predominant negative symptoms of schizophrenia treated with cariprazine compared with risperidone. Materials & methods: A Markov model was built, based on the Mohr-lenert approach and data derived from clinical trials, to estimate potential QAlY gains of patients. Results: Patients had higher probability of reaching better health states treated with cariprazine compared with risperidone. In the model, this resulted in an estimated QAlY gain of 0.029 per patient, after 1 year of treatment. Conclusion: Cariprazine, which showed clinically meaningful improvement in the symptoms, and personal and social performance, can also provide significant QAlY gain in the treatment of patients with predominant negative symptoms of schizophrenia compared with risperidone.

Original languageEnglish
Pages (from-to)639-648
Number of pages10
JournalJournal of Comparative Effectiveness Research
Volume6
Issue number8
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Risperidone
Quality-Adjusted Life Years
Schizophrenia
cariprazine
Clinical Trials
Health
Therapeutics

Keywords

  • cariprazine
  • quality of life
  • schizophrenia

ASJC Scopus subject areas

  • Health Policy

Cite this

Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. / Németh, Bertalan; Molnár, Anett; Akehurst, Ron; Horváth, Margit; Kóczián, Kristóf; Németh, György; Götze, Árpád; Vokó, Z.

In: Journal of Comparative Effectiveness Research, Vol. 6, No. 8, 01.11.2017, p. 639-648.

Research output: Contribution to journalArticle

Németh, Bertalan ; Molnár, Anett ; Akehurst, Ron ; Horváth, Margit ; Kóczián, Kristóf ; Németh, György ; Götze, Árpád ; Vokó, Z. / Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. In: Journal of Comparative Effectiveness Research. 2017 ; Vol. 6, No. 8. pp. 639-648.
@article{d9e79e5589ff4f79b95af8cefcce59b7,
title = "Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone",
abstract = "Aim: Our study aimed at estimating differences in quality-adjusted life year (QAlY) gain for patients with predominant negative symptoms of schizophrenia treated with cariprazine compared with risperidone. Materials & methods: A Markov model was built, based on the Mohr-lenert approach and data derived from clinical trials, to estimate potential QAlY gains of patients. Results: Patients had higher probability of reaching better health states treated with cariprazine compared with risperidone. In the model, this resulted in an estimated QAlY gain of 0.029 per patient, after 1 year of treatment. Conclusion: Cariprazine, which showed clinically meaningful improvement in the symptoms, and personal and social performance, can also provide significant QAlY gain in the treatment of patients with predominant negative symptoms of schizophrenia compared with risperidone.",
keywords = "cariprazine, quality of life, schizophrenia",
author = "Bertalan N{\'e}meth and Anett Moln{\'a}r and Ron Akehurst and Margit Horv{\'a}th and Krist{\'o}f K{\'o}czi{\'a}n and Gy{\"o}rgy N{\'e}meth and {\'A}rp{\'a}d G{\"o}tze and Z. Vok{\'o}",
year = "2017",
month = "11",
day = "1",
doi = "10.2217/cer-2017-0024",
language = "English",
volume = "6",
pages = "639--648",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone

AU - Németh, Bertalan

AU - Molnár, Anett

AU - Akehurst, Ron

AU - Horváth, Margit

AU - Kóczián, Kristóf

AU - Németh, György

AU - Götze, Árpád

AU - Vokó, Z.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Aim: Our study aimed at estimating differences in quality-adjusted life year (QAlY) gain for patients with predominant negative symptoms of schizophrenia treated with cariprazine compared with risperidone. Materials & methods: A Markov model was built, based on the Mohr-lenert approach and data derived from clinical trials, to estimate potential QAlY gains of patients. Results: Patients had higher probability of reaching better health states treated with cariprazine compared with risperidone. In the model, this resulted in an estimated QAlY gain of 0.029 per patient, after 1 year of treatment. Conclusion: Cariprazine, which showed clinically meaningful improvement in the symptoms, and personal and social performance, can also provide significant QAlY gain in the treatment of patients with predominant negative symptoms of schizophrenia compared with risperidone.

AB - Aim: Our study aimed at estimating differences in quality-adjusted life year (QAlY) gain for patients with predominant negative symptoms of schizophrenia treated with cariprazine compared with risperidone. Materials & methods: A Markov model was built, based on the Mohr-lenert approach and data derived from clinical trials, to estimate potential QAlY gains of patients. Results: Patients had higher probability of reaching better health states treated with cariprazine compared with risperidone. In the model, this resulted in an estimated QAlY gain of 0.029 per patient, after 1 year of treatment. Conclusion: Cariprazine, which showed clinically meaningful improvement in the symptoms, and personal and social performance, can also provide significant QAlY gain in the treatment of patients with predominant negative symptoms of schizophrenia compared with risperidone.

KW - cariprazine

KW - quality of life

KW - schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85035326047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035326047&partnerID=8YFLogxK

U2 - 10.2217/cer-2017-0024

DO - 10.2217/cer-2017-0024

M3 - Article

AN - SCOPUS:85035326047

VL - 6

SP - 639

EP - 648

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6305

IS - 8

ER -